Experiences with
Small lymphocytic lymphoma (SLL)813 public posts
Improving Treatment Options for Patients with Double Refractory CLL - patients who progressed after treatment with both cBTKis and BCL2i
Approvals of multiple covalent Bruton's tyrosine kinas inhibitors (cBTKis) as well as the B-cell lymphoma-2 inhibitor (BCL2i) venetoclax targeting these pathways have revolutionized the treatment of CLL and small lymphocytic lymphoma (SLL).
"Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma: unraveling CLL/SLL biological gray zone in the era of novel therapies
leukemia/small lymphocytic lymphoma (A-CLL/SLL) is a histologically aggressive subtype of CLL/SLL that lies in between conventional CLL/SLL (C-CLL/SLL) and Richter transformation (RT) on the biological spectrum.
Want to take advantage of all our features? Just log in!
or
Review article summarises management strategies for those with CLL harbouring complex karyotype
On 6 January 2025, the journal [i]BJ Haem[/i] published a review article titled [i]Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype[/i] written by a team from Padua, Italy. The article summary explains its aims:
[i]"Chronic lymphocytic leukaemia
Wednesday's Word
[u][i]Golexanolone[/i][/u]
[i]A relatively new drug that is in clinical trial mostly being tested to help relieve cognitive and motor functions. It is hopefully to be used for Parkinson patients as well as those with hepatic encephalopathy in PBC. it was being tested in the laboratories